119-sres477

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 477 Introduced in Senate

    (IS) ]

<DOC>

119th CONGRESS
 1st Session
S. RES. 477

 Designating the first full week in May as ``Tardive Dyskinesia 
 Awareness Week''.

_______________________________________________________________________

 IN THE SENATE OF THE UNITED STATES

 October 30, 2025

 Mr. Mullin (for himself and Mr. Padilla) submitted the following 
 resolution; which was referred to the Committee on the Judiciary

_______________________________________________________________________

 RESOLUTION

 Designating the first full week in May as ``Tardive Dyskinesia 
 Awareness Week''.

Whereas serious mental illnesses like bipolar disorder, major depressive 
 disorder, and schizophrenia often require treatment with antipsychotic 
 medications for effective management and antipsychotic prescribing rates 
 continue to rise;
Whereas, while prolonged antipsychotic use may be essential for the treatment of 
 certain conditions, it is associated with tardive dyskinesia (referred 
 to in this preamble as ``TD''), a condition marked by uncontrollable, 
 abnormal, and repetitive movements of the face, torso, limbs, or 
 extremities;
Whereas people at higher risk of TD include those older than 55 years of age, 
 Black individuals, women, individuals with mood or substance use 
 disorders, intellectual disabilities, or central nervous system 
 injuries, and those with high cumulative antipsychotic exposure;
Whereas approximately 60 percent of the estimated 800,000 adults living with TD 
 in the United States remain undiagnosed and even mild TD symptoms can be 
 stigmatizing and impair physical, social, and emotional well-being, 
 underscoring the urgency of early screening, detection, and 
 intervention;
Whereas the American Psychiatric Association recommends routine TD screening in 
 its clinical guidelines for antipsychotic treatment and individuals 
 treated with antipsychotics or experiencing abnormal movements should 
 consult their healthcare providers to assess TD risk, receive TD 
 screenings, and determine appropriate treatment together;
Whereas treatments approved for TD by the Food and Drug Administration can 
 provide options for symptom management and improved quality of life for 
 many individuals living with TD; and
Whereas the Senate can encourage TD screening education and awareness for health 
 care providers, patients, and care partners to help ensure patients 
 prescribed antipsychotics receive care and support that aligns with 
 clinical best practice, including regular TD screenings: Now, therefore, 
 be it
 Resolved, That the Senate--

    (1) designates the first full week in May as ``Tardive 
 Dyskinesia Awareness Week''; and

    (2) in recognition and support of Tardive Dyskinesia 
 Awareness Week--
        (A) underscores the importance of early detection 
 and intervention to improve outcomes for individuals 
 living with mental health conditions and individuals 
 prescribed antipsychotics; and
        (B) supports efforts to raise awareness about the 
 causes and symptoms of tardive dyskinesia and the 
 importance of routine tardive dyskinesia screening.
 <all>